Genetu Bayih Abebe, Debnath Anjan, Mitre Edward, Huston Christopher D, Laleu Benoît, Leroy Didier, Blasco Benjamin, Campo Brice, Wells Timothy N C, Willis Paul A, Sjö Peter, Van Voorhis Wesley C, Pillai Dylan R
Department of Pathology, Medicine, and Microbiology, University of Calgary, Calgary, AB, Canada.
Department of Medical Parasitology, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.
Clin Microbiol Rev. 2017 Jul;30(3):647-669. doi: 10.1128/CMR.00111-16.
In the last 2 decades, renewed attention to neglected tropical diseases (NTDs) has spurred the development of antiparasitic agents, especially in light of emerging drug resistance. The need for new drugs has required screening methods using parasite culture. Furthermore, clinical laboratories sought to correlate susceptibility methods with treatment outcomes, most notably with malaria. Parasites with their various life cycles present greater complexity than bacteria, for which standardized susceptibility methods exist. This review catalogs the state-of-the-art methodologies used to evaluate the effects of drugs on key human parasites from the point of view of drug discovery as well as the need for laboratory methods that correlate with clinical outcomes.
在过去20年里，对被忽视热带病（NTDs）的重新关注推动了抗寄生虫药物的研发，尤其是鉴于新出现的耐药性问题。对新药的需求促使人们采用寄生虫培养的筛选方法。此外，临床实验室试图将药敏试验方法与治疗结果相关联，尤其是疟疾。寄生虫具有多种生命周期，比已存在标准化药敏试验方法的细菌更为复杂。本综述从药物研发的角度以及对与临床结果相关的实验室方法的需求出发，梳理了用于评估药物对主要人体寄生虫作用的最新方法。
